미국 약사

07/31/2026

https://www.msn.com/en-us/health/other/replimune-surges-after-fda-advisers-back-skin-cancer-drug/ar-AA297a8U

By Christy Santhosh July 31 (Reuters) - Shares of Replimune more than doubled premarket on Friday after the U.S. Food and Drug Administration's panel of outside advisers voted to back trial results for its drug for a type of skin cancer. Late on Thursday, the panel voted 10 to 3 in favor of the drug...

07/29/2026

https://www.msn.com/en-us/health/other/brazil-greenlights-five-new-injectable-diabetes-drugs/ar-AA28YG4M

By Luciana Magalhaes SAO PAULO, July 29 (Reuters) - Brazil's health regulator Anvisa on Wednesday said it approved five new injectable GLP-1 drugs for diabetes and obesity treatment, capitalizing on a wave of expedited regulatory reviews following the expiration of Ozempic’s patent in the country ...

07/29/2026

https://www.msn.com/en-us/health/other/us-fda-approves-first-freeze-dried-plasma-product-for-use/ar-AA28ZNVl

07/29/2026

https://www.msn.com/en-us/technology/tech-companies/us-ftc-sues-hims-hers-for-sending-user-health-info-to-meta-snap/ar-AA28ZFEz

By Jody Godoy July 29 (Reuters) - The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared users' health data with online advertisers, despite promising privacy, and engaged in deceptive billing and cancellation practices. Users' sensitive health inform...

07/28/2026

https://www.msn.com/en-us/money/companies/johnson-johnson-agrees-to-pay-5-5-billion-to-settle-talc-lawsuits/ar-AA28OiQ2

The drugmaker aims to put an end to litigation that has been going on for more than a decade.

07/27/2026

Forte Biosciences
— The biotech stock rallied more than 39% on news it will be acquired by Netherlands-headquartered Argenx
for $2.2 billion in cash, or $77 per share. The deal, expected to close in the third quarter, represents a premium of 40% from Forte’s close of $54.78 on Friday. U.S.-listed shares of Argenx were down marginally in the premarket.

Forte Biosciences (NASDAQ:FBRX) shares climbed 39.2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.2 billion. Under the terms of the agreement, argenx will pa...

07/27/2026

https://www.reuters.com/legal/litigation/argenx-buy-forte-biosciences-about-22-billion-2026-07-27/

Belgian-Dutch immunology company argenx ​will buy ‌Forte Biosciences to add experimental ​autoimmune drug ​FB102 to its portfolio, ⁠the company ​said on ​Monday.

07/26/2026

https://www.reuters.com/legal/litigation/nestle-pushes-simpler-us-food-labels-shed-frankenstein-ingredients-image-2026-07-24/

As shoppers increasingly scrutinise ingredient labels ​to avoid products perceived as heavily processed, Nestle , maker of Nescafe coffee and KitKat chocolate, has been lobbying U.S. authorities to ‌allow simpler descriptions using common rather than scientific names on packaging.

07/26/2026

https://www.msn.com/en-us/money/general/merck-licenses-experimental-hiv-pill-to-generic-makers-in-129-countries/ar-AA28BTlY

07/25/2026

https://www.msn.com/en-us/money/general/ai-shortens-drug-discovery-to-around-1-year-in-china-insilico-ceo-says/ar-AA28C5Kv

By Laurie Chen SHANGHAI, July 23 (Reuters) - Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said, giving it an edge over traditional Western pharmaceutical giants. Its strategy highlights how China's....